체외 충격파 결석파쇄술 시장 : 세계 시장 예측(2026-2032년)

The Extracorporeal Shock Wave Lithotripsy Market is projected to grow by USD 602.68 million at a CAGR of 6.69% by 2032.

Extracorporeal Shock Wave Lithotripsy Executive Summary

Extracorporeal shock wave lithotripsy (ESWL) remains a cornerstone non-invasive treatment for urinary stone disease, particularly renal and upper ureteral calculi that are suitable by size, location, composition, and patient anatomy. The procedure uses externally generated acoustic shock waves focused on stones to fragment them into passable particles, reducing the need for incisions and supporting same-day care in many settings. Clinical adoption is closely tied to the global burden of urolithiasis, which is associated with low fluid intake, dehydration, dietary sodium intake, obesity, metabolic syndrome, recurrent urinary tract infections, and climate-related heat exposure. Current practice emphasizes appropriate patient selection, imaging-based stone characterization, radiation-conscious workflows, and post-procedure follow-up to confirm stone clearance and manage recurrence risk. As healthcare systems prioritize minimally invasive urology, ESWL continues to be evaluated alongside ureteroscopy and percutaneous nephrolithotomy based on stone-free outcomes, retreatment rates, anesthesia requirements, complication profiles, patient preference, and total care pathway efficiency.

Transformative Shifts in the ESWL Landscape

The ESWL landscape is being reshaped by a stronger focus on precision targeting, patient-centered care, and evidence-based procedure selection. Modern systems increasingly integrate ultrasound and fluoroscopic guidance to improve stone localization while helping clinicians limit radiation exposure where feasible. Urology guidelines continue to refine indications by stone burden, lower pole anatomy, skin-to-stone distance, stone density on computed tomography, and suspected composition, all of which influence fragmentation success. Operationally, ambulatory surgery centers and outpatient hospital departments are expanding the role of ESWL where reimbursement, trained staffing, and device access support efficient throughput. At the same time, ureteroscopy has gained preference for certain stone profiles due to immediate visual treatment and higher single-session clearance in selected cases, placing pressure on ESWL providers to demonstrate optimized protocols, reduced retreatment, and better patient stratification. The shift is therefore not away from ESWL, but toward more disciplined use in cases where non-invasive kidney stone treatment offers meaningful clinical and economic advantages.

Cumulative Impact of Artificial Intelligence on ESWL

Artificial intelligence is beginning to influence ESWL through image interpretation, treatment planning, and clinical decision support rather than replacing clinician judgment. AI-enabled imaging tools can support automated stone detection, volumetric assessment, and Hounsfield unit evaluation on computed tomography, helping estimate fragmentation likelihood and guide modality selection. Machine learning models are also being investigated to predict ESWL success using variables such as stone size, location, density, skin-to-stone distance, body mass index, hydronephrosis, and prior stone history. In procedural settings, AI-assisted targeting and motion-compensation concepts may help address respiratory movement and improve energy delivery consistency, although broad clinical validation and workflow integration remain essential. Beyond the procedure, predictive analytics can help identify patients at elevated risk of recurrence, prompting metabolic evaluation, hydration counseling, dietary modification, and pharmacologic prevention when clinically indicated. The cumulative impact of artificial intelligence is expected to be strongest where it improves patient selection, standardizes imaging interpretation, reduces avoidable procedures, and supports measurable outcomes in kidney stone management.

Key Regional Insights Across Global ESWL Adoption

Asia-Pacific is a high-priority region for ESWL because populous countries face rising kidney stone incidence linked to urbanization, dietary sodium intake, diabetes, obesity, and hot climates that increase dehydration risk. In North America, established urology infrastructure, broad access to computed tomography and ultrasound imaging, and mature outpatient care pathways support continued use of ESWL for appropriately selected stones, while clinical practice increasingly compares outcomes with ureteroscopy. Latin America shows demand tied to improving specialty care access and the need for cost-conscious, minimally invasive treatment, although availability may vary between major urban hospitals and underserved regions. Europe benefits from standardized clinical guidelines, strong emphasis on radiation protection, and integrated stone centers that use ESWL within a multimodal urology framework. The Middle East presents sustained procedural relevance due to hot weather, dehydration exposure, and a recognized stone disease burden, with advanced hospitals investing in non-invasive and endoscopic urology. Africa remains heterogeneous, with ESWL access concentrated in larger referral centers and opportunities linked to diagnostic capacity, workforce training, device maintenance, and broader access to safe kidney stone disease treatment.

Key Group Insights Shaping ESWL Demand

ASEAN demand for ESWL is influenced by growing urban healthcare capacity, expanding private hospital networks, and climatic conditions that can contribute to recurrent stone formation, with adoption strongest where imaging and urology specialist access are concentrated. GCC countries show a clear clinical need for kidney stone interventions due to heat exposure, dehydration risk, and high prevalence of metabolic conditions, supporting investment in advanced urology services and outpatient treatment models. The European Union provides a highly regulated environment shaped by device safety standards, clinical guideline adherence, and radiation-dose management, encouraging structured ESWL use within evidence-based care pathways. BRICS countries combine large patient populations with uneven healthcare access, creating opportunities for scalable non-invasive stone treatment while underscoring the importance of affordability, maintenance infrastructure, and specialist training. G7 countries are characterized by sophisticated urology networks, aging populations, advanced imaging availability, and strong scrutiny of comparative effectiveness between ESWL and endourological alternatives. NATO member countries, many of which overlap with high-income healthcare systems, generally emphasize resilient hospital infrastructure, technology-enabled care delivery, and standardized clinical practices, supporting ESWL use where clinical indications and reimbursement frameworks align.

Key Country Insights for ESWL Care Pathways

The United States has a well-established kidney stone treatment ecosystem, with ESWL used in hospitals and outpatient settings alongside ureteroscopy and percutaneous procedures, guided by clinical guidelines and payer scrutiny of repeat interventions. Canada emphasizes evidence-based specialty care and access through regional health systems, with ESWL availability often tied to hospital-based urology programs. Mexico and Brazil show increasing need for minimally invasive stone management as urban centers expand specialist services, while access gaps remain in rural and lower-resource areas. The United Kingdom, Germany, France, Italy, and Spain integrate ESWL within guideline-driven urology pathways, supported by diagnostic imaging, referral networks, and quality-focused public or mixed healthcare systems; Germany and France also demonstrate strong procedural standardization in specialist environments. Russia presents a large geographic care-delivery challenge, making regional availability and referral infrastructure important for ESWL access. China and India face substantial kidney stone burdens due to population scale, dietary transitions, and climate-related dehydration in many regions, with leading hospitals using advanced stone management while broader access depends on equipment distribution and trained personnel. Japan and South Korea combine advanced imaging, aging populations, and high clinical technology adoption, supporting precision-oriented ESWL use. Australia applies ESWL within a developed urology system where patient geography, referral pathways, and access to regional specialist centers influence treatment delivery.

Actionable Recommendations for ESWL Industry Leaders

Industry leaders should prioritize clinically validated patient-selection tools that improve ESWL success rates and reduce unnecessary retreatment. Investment in imaging integration, ultrasound-guided workflows, dose-conscious fluoroscopy, and user-friendly targeting interfaces can strengthen procedural efficiency and safety. Providers should develop standardized protocols covering stone assessment, analgesia, energy escalation, shock rate, follow-up imaging, and recurrence prevention counseling. Device manufacturers and service partners should emphasize uptime, preventive maintenance, training, and lifecycle support, particularly in regions where equipment reliability determines access. Healthcare organizations can improve outcomes by embedding ESWL into multidisciplinary stone clinics that include metabolic evaluation, nutrition guidance, hydration counseling, and long-term prevention. Stakeholders should also generate real-world evidence comparing ESWL outcomes by stone density, location, burden, and patient anatomy, ensuring that positioning remains grounded in measurable clinical value rather than procedure volume alone.

Research Methodology for ESWL Insights

This executive summary is developed using a secondary research approach grounded in publicly available, clinically credible, and regulatory-relevant sources. Inputs include urology association guidelines, peer-reviewed medical literature, public health data on urolithiasis risk factors, device safety frameworks, hospital care pathway documentation, and regional healthcare infrastructure indicators. The analysis excludes market sizing, revenue estimation, market share ranking, and forecasting, focusing instead on clinical adoption drivers, technology shifts, regional access patterns, and evidence-based decision factors. Insights are synthesized through triangulation of disease burden indicators, treatment guideline recommendations, imaging and procedural standards, and healthcare delivery characteristics. Emphasis is placed on verified themes such as minimally invasive stone treatment, ESWL patient selection, artificial intelligence in medical imaging, outpatient urology workflows, radiation reduction, and recurrence prevention in kidney stone disease.

Conclusion: ESWL's Role in Modern Stone Management

Extracorporeal shock wave lithotripsy continues to play an important role in kidney stone treatment where stone characteristics, patient anatomy, and care setting support non-invasive fragmentation. Its future competitiveness depends on precision selection, reliable imaging guidance, optimized treatment protocols, and integration with broader stone prevention strategies. Artificial intelligence, advanced imaging analytics, and standardized outpatient workflows can enhance the value of ESWL by improving procedural planning and reducing variability. Regional and country-level adoption will remain shaped by urology infrastructure, climate-related stone risk, reimbursement models, equipment access, and trained specialist availability. For healthcare leaders, the strategic priority is to position ESWL not as a universal solution, but as a high-value option within an evidence-based continuum of urinary stone disease management.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Extracorporeal Shock Wave Lithotripsy Market, by Technology

• 7.1. Introduction
• 7.2. Electrohydraulic
• 7.3. Electromagnetic
• 7.4. Piezoelectric

8. Extracorporeal Shock Wave Lithotripsy Market, by Portability

• 8.1. Introduction
• 8.2. Mobile
• 8.3. Stationary

9. Extracorporeal Shock Wave Lithotripsy Market, by Treatment Mode

• 9.1. Introduction
• 9.2. Inpatient
• 9.3. Outpatient

10. Extracorporeal Shock Wave Lithotripsy Market, by Application

• 10.1. Introduction
• 10.2. Gallbladder Stones
• 10.3. Renal Calculi
• 10.4. Ureteral Calculi

11. Extracorporeal Shock Wave Lithotripsy Market, by End User

• 11.1. Introduction
• 11.2. Ambulatory Surgical Centers
  • 11.2.1. Freestanding Centers
  • 11.2.2. Hospital Based Centers
• 11.3. Clinics
  • 11.3.1. Multispecialty Clinics
  • 11.3.2. Urology Clinics
• 11.4. Hospitals
  • 11.4.1. Private Hospitals
  • 11.4.2. Public Hospitals

12. Extracorporeal Shock Wave Lithotripsy Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Extracorporeal Shock Wave Lithotripsy Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Extracorporeal Shock Wave Lithotripsy Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. FPNV Positioning Matrix, 2025
• 15.3. Market Concentration Analysis, 2025
  • 15.3.1. Concentration Ratio (CR)
  • 15.3.2. Herfindahl Hirschman Index (HHI)
• 15.4. Recent Developments & Impact Analysis, 2025
• 15.5. Product Portfolio Analysis, 2025
• 15.6. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Allengers Medical Systems
• 16.2. ARI Medical Technology Co., Ltd.
• 16.3. Dornier MedTech GmbH
• 16.4. EDAP TMS SA
• 16.5. ELMED Medical Systems
• 16.6. Elvation Medical
• 16.7. EMS Electro Medical Systems SA
• 16.8. GEMSS Co., Ltd.
• 16.9. Inceler Medikal Ltd.
• 16.10. Likamed GmbH
• 16.11. Medispec
• 16.12. MTS Medical AG
• 16.13. Nanjing Kapu Technology Co., Ltd.
• 16.14. Northern Litho, Inc.
• 16.15. Olympus Corporation
• 16.16. PT LUMINA PROCARE MEDITECH
• 16.17. Richard Wolf GmbH.
• 16.18. Shenzhen Hyde Medical Equipment
• 16.19. Shenzhen Wikkon Precision Technologies Co., Ltd.
• 16.20. Siemens Healthineers AG
• 16.21. Storz Medical AG
• 16.22. The Direx Group
• 16.23. United Medical Systems Inc.
• 16.24. Zimmer MedizinSysteme GmbH